FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Smith Cynthia						2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [ AGIO ]										eck all appli Directo	cable) or	g Pers	10% Ov	ner	
(Last)	(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC.																Officer (give title below)		Other (s below)	pecity	
88 SIDNEY STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person					
(Street)	IDGE N	ИΑ	02139														iled by Mor		orting Persoi one Repor		
(City) (State) (Zip)					Rı	Rule 10b5-1(c) Transaction Indication															
							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - Nor	n-Deriv	ative	Sec	curiti	ies Ac	qu	ired,	Disp	osed o	of, o	r Ben	eficial	ly Owne	t				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D						ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		Ĺ	3. Transaction Code (Instr. 8)						Securitie Benefici Owned	5. Amount of Securities Beneficially Owned Following Reported		r Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										Code	v	Amount		(A) or (D)	Price	Transac (Instr. 3	tion(s)			msu. 4)	
Common stock 08/11/						4				M		2,30	2	A	\$0	7,	992		D		
		7	able II -									sed of onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversior or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		ransaction Code (Instr.		of		6. Date Exercisable a Expiration Date (Month/Day/Year)			d 7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exc	te ercisabl		xpiration ate	Title	1	Amount or lumber of Shares						
Restricted	(1)	08/11/2024			M			2,302		(2)		(2)	Com	nmon	2,302	\$0	2,302		D		

### **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

#### Remarks:

/s/ William Cook, as attorneyin-fact for Cynthia Smith

\*\* Signature of Reporting Person Date

08/13/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.